Vycor Medical Releases Financial Results for the Three And Nine Months Ended September 30, 2026
VYCOR MEDICAL INC (VYCO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vycor Medical Releases Financial Results for the Three And Nine Months Ended September 30, 2026 BOCA RATON, FL (November 13, 2026) – Vycor Medical, Inc. (“Vycor”) (OTCQB—VYCO), today announced financial results for the three and nine months ended September 30, 2026.
How this was made
The 30-second read
Why it matters
The earnings release shows a contraction in core device sales and modest growth in the development division, suggesting near‑term revenue pressure.
Market read
First‑time disclosure of a micro‑cap earnings beat with declining metrics; likely to move the stock modestly lower on the day.
What to watch
Recent peer‑reviewed studies on the ViewSite system could drive future adoption despite short‑term sales lag.
Background
Vycor Medical (OTCQB:VYCO) operates the ViewSite™ Brain Access System and is developing a visual‑rehab platform, NovaVision.
Ticker impact
Vycor Medical filed an 8‑K reporting Q3 and nine‑month results showing double‑digit revenue declines and lower operating profit.
downward pressure as investors price in lower sales and profit
The disclosed numbers are the first public release and show material deterioration versus the prior year.
Market effects
May weigh on other small‑cap medical device stocks as the decline highlights demand softness.
Limited to U.S. OTC market; no broader regional effect.
Minimal global impact; confined to niche neurosurgical device segment.
Counterpoint
If the company can secure new hospital contracts, the dip may be temporary and present a buying opportunity at lower valuation.
Key entities
- CompanyVycor Medical Inc.
Medical device maker reporting Q3 2026 results.

